Illumina Inc

ILMN is exhibiting persistent lower highs and lower lows, confirming a medium-term bearish bias despite a longer-term uptrend. Price is currently testing the 50-day SMA support zone with 9- and 20-day EMAs overhead acting as resistance. Short-term timing remains unfavorable for a bearish entry until a bounce into the EMA resistance area provides a clear rejection. A deferred sell (trim) into the $209–$210 resistance zone is advised.

• ↑Q2 2026 revenue reached $1.16B (+9.5% YoY) on 15% clinical consumables growth
• ↑Non-GAAP operating margin 22.5% and gross margin 68.2%, with 150 bp sequential expansion guided
• ↓Research revenues may fall mid-to-high single digits amid NIH funding uncertainty